WO2024012502A1 - Composition et son procédé d'utilisation - Google Patents

Composition et son procédé d'utilisation Download PDF

Info

Publication number
WO2024012502A1
WO2024012502A1 PCT/CN2023/107076 CN2023107076W WO2024012502A1 WO 2024012502 A1 WO2024012502 A1 WO 2024012502A1 CN 2023107076 W CN2023107076 W CN 2023107076W WO 2024012502 A1 WO2024012502 A1 WO 2024012502A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
subject
disease
composition
oct4
Prior art date
Application number
PCT/CN2023/107076
Other languages
English (en)
Chinese (zh)
Inventor
季银
刘霞
伍瑶
Original Assignee
南京瑞初医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京瑞初医药有限公司 filed Critical 南京瑞初医药有限公司
Publication of WO2024012502A1 publication Critical patent/WO2024012502A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • compositions and methods have long been sought for rejuvenating cells to restore them from an aging, mature state to a younger, more vibrant state of life, to treat certain injuries and diseases, and to generally reverse and Prevents aging of the entire organism.
  • iPSC induced pluripotent stem cell
  • This epoch-making cell technology reprograms cells through four transcription factors (Oct4, Sox2, Klf4 and c-Myc) and uses viral vectors to combine the four transcription factors (Oct4, Sox2, Klf4 and c-Myc).
  • -Myc is transferred into differentiated somatic cells to reprogram them to obtain a cell type similar to embryonic stem cells.
  • This kind of cells is similar to human embryonic stem cells and has super differentiation ability. It can differentiate into human blood cells, bone cells, nerve cells, etc., and then cultivate human organs, bones, cornea, pancreas, etc. It has huge application prospects in disease simulation, drug screening and cell therapy.
  • the present invention relates to a composition for rejuvenating cells, tissues or organs in a subject based on only one factor or two factors, and methods of rejuvenating cells, tissues or organs in a subject using said composition,
  • the compositions and methods are capable of rejuvenating or restoring function to cells, tissues or organs in a subject.
  • the compositions and methods may be used in any disease or injury requiring repair or replacement of dysfunctional tissue.
  • the present invention provides a composition for rejuvenating cells, tissues or organs in a subject, said composition comprising factor OCT4.
  • the composition further comprises any one factor selected from SOX1, SOX2, SOX3 and GMNN.
  • the composition includes OCT4 and SOX2.
  • the composition includes OCT4, and any one factor selected from SOX1, SOX3, and GMNN.
  • the factor is a protein, a nucleic acid encoding the same, or a mixture thereof.
  • the OCT4, SOX1, SOX2, SOX3, and GMNN are proteins, fusion proteins combined with a permeable membrane domain, and encode nucleic acids, such as DNA or RNA.
  • the factors are provided in the form of an expression vector, which can be a plasmid vector, an episomal vector, a transposon, a virus-derived vector, such as an adenovirus vector, an adeno-associated virus vector (AAV) , lentiviral vectors, Sendai virus vectors, cytomegalovirus vectors or vaccinia virus vectors.
  • a virus-derived vector such as an adenovirus vector, an adeno-associated virus vector (AAV) , lentiviral vectors, Sendai virus vectors, cytomegalovirus vectors or vaccinia virus vectors.
  • the factors are present on one or more expression vectors.
  • the factors are present on the same expression vector.
  • the factor is in the form of mRNA.
  • the factors are concatenated on the same mRNA molecule, or each of the factors is on a different mRNA molecule, and the factors are in the form of a compound of multiple mRNA molecules.
  • the factor is a synthetic mRNA encoding a wild-type form, a mutant, or a genetically engineered form selected from the group consisting of OCT4, SOX1, SOX2, SOX3, GMNN.
  • the composition further includes a pharmaceutically acceptable carrier or adjuvant.
  • the subject is a mammal including, but not limited to, human, mouse, rat, bovine, ovine, equine, canine, feline, pig, or monkey.
  • the subject cells, tissues or organs are from, but are not limited to, eyes, ears, nose, mouth, including gums and tooth roots; bones, lungs, breasts, pancreas, stomach, esophagus; muscles, including cardiac muscle; Liver, blood vessels; skin, including hair; heart, brain, nervous tissue, kidneys, testicles, prostate, penis, cloaca, fins, ovaries, or intestines.
  • the composition for rejuvenating cells, tissues or organs of a subject is capable of restoring epigenetic information to the cells, tissues or organs of the subject.
  • the composition for rejuvenating cells, tissues or organs of a subject is capable of restoring the loss of epigenetic information due to aging, injury or disease to the cells, tissues or organs of the subject.
  • the expression of promoter regulatory factors can be employed to reduce and reverse epigenetic marks associated with aging, increase epigenetic marks associated with cellular rejuvenation, reduce expression of aging-associated proteins, and increase epigenetic markers associated with cellular rejuvenation.
  • the expression of rejuvenation-related proteins restores the balance between euchromatin and heterochromatin, prevents the loss of cell identity, restores cell identity, and reverses aging-related DNA methylation changes, thereby rejuvenating cells.
  • the OCT4, SOX1, SOX2, SOX3, GMNN is a human protein, or a non-human protein, e.g., a mammal (e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird), or a protein that has at least 80% identity with the amino acid sequence of the corresponding human protein or non-human protein and maintains activity.
  • a mammal e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird
  • a protein that has at least 80% identity with the amino acid sequence of the corresponding human protein or non-human protein and maintains activity e.g., a mammal (e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird), or a
  • the OCT4, SOX1, SOX2, SOX3, GMNN is a nucleic acid encoding a human protein, or a nucleic acid encoding a non-human protein, e.g., encoding a mammal (e.g., mouse, rat, cow, sheep, horse, dog, cat, pig, monkey, chicken, duck, goose, bird), or have at least 80% identity and maintain identity with the corresponding nucleic acid encoding a human protein, or a nucleic acid sequence encoding a non-human protein Active nucleic acids.
  • a mammal e.g., mouse, rat, cow, sheep, horse, dog, cat, pig, monkey, chicken, duck, goose, bird
  • the composition induces cell reprogramming, reverses aging, improves tissue function, improves organ function, promotes tissue repair, promotes tissue survival, promotes tissue regeneration, promotes tissue growth, promotes angiogenesis, and reduces scarring, Reduces the external manifestations of aging including alopecia, hair thinning, hair graying, skin laxity and skin wrinkles, promotes organ regeneration, promotes organ survival, treats disease, or any combination thereof.
  • the composition reverses aging of cells, tissues, organs or subjects, thereby rejuvenating said cells, tissues, organs.
  • the composition can promote axonal regeneration of neuronal cells in a subject.
  • the composition can proliferate skin fibroblasts in a subject.
  • the composition can promote chondrocyte proliferation in a subject.
  • the composition can promote muscle stem cell proliferation in a subject.
  • the methods can reverse senescence in skin fibroblasts in a subject.
  • the composition can reverse chondrocyte senescence.
  • the composition does not induce teratoma formation.
  • the composition does not induce complete reprogramming.
  • the composition does not reprogram cells to an induced pluripotent stem cell (ipsc) state.
  • ipsc induced pluripotent stem cell
  • the present invention provides a method for rejuvenating cells, tissues or organs in a subject, the method comprising administering the composition of the first aspect to the subject.
  • the composition includes factor OCT4.
  • the composition includes factor OCT4 and any one factor selected from the group consisting of SOX1, SOX2, SOX3, and GMNN.
  • the composition includes OCT4 and SOX2.
  • the composition includes OCT4, and any one factor selected from SOX1, SOX3, and GMNN.
  • the factor is a protein, a nucleic acid encoding the same, or a mixture thereof.
  • the OCT4, SOX1, SOX2, SOX3, and GMNN are proteins, fusion proteins combined with a permeable membrane domain, and encode nucleic acids, such as DNA or RNA.
  • the factors are provided in the form of an expression vector, which can be a plasmid vector, an episomal vector, a transposon, a virus-derived vector, such as an adenovirus vector, an adeno-associated virus vector (AAV) , lentiviral vector, Sendai virus vector, cytomegalovirus vector, vaccinia virus vector.
  • a virus-derived vector such as an adenovirus vector, an adeno-associated virus vector (AAV) , lentiviral vector, Sendai virus vector, cytomegalovirus vector, vaccinia virus vector.
  • the factors are present on one or more expression vectors.
  • the factors are present on the same expression vector.
  • the factor is in the form of mRNA.
  • the factors are concatenated on the same mRNA molecule, or each of the factors is on a different mRNA molecule, and the factors are in the form of a compound of multiple mRNA molecules.
  • the factor is a synthetic mRNA encoding a wild-type form, a mutant, or a genetically engineered form selected from the group consisting of OCT4, SOX1, SOX2, SOX3, GMNN.
  • the composition further includes a pharmaceutically acceptable carrier or adjuvant.
  • the subject is a mammal including, but not limited to, human, mouse, rat, bovine, ovine, equine, canine, feline, pig, or monkey.
  • the subject is a chicken, duck, goose or bird.
  • the subject cells, tissues or organs are from, but are not limited to, eyes, ears, nose, mouth, including gums and tooth roots; bones, lungs, breasts, pancreas, stomach, esophagus; muscles, including cardiac muscle; Liver, blood vessels; skin, including hair; heart, brain, nervous tissue, kidneys, testicles, prostate, penis, cloaca, fins, ovaries, or intestines.
  • the composition for rejuvenating cells, tissues or organs of a subject is capable of restoring epigenetic information to the cells, tissues or organs of the subject.
  • the composition for rejuvenating cells, tissues or organs of a subject is capable of restoring the loss of epigenetic information due to aging, injury or disease to the cells, tissues or organs of the subject.
  • the expression of promoter regulatory factors can be employed to reduce and reverse epigenetic marks associated with aging, increase epigenetic marks associated with cellular rejuvenation, reduce expression of aging-associated proteins, and increase epigenetic markers associated with cellular rejuvenation.
  • the expression of rejuvenation-related proteins restores the balance between euchromatin and heterochromatin, prevents the loss of cell identity, restores cell identity, and reverses aging-related DNA methylation changes, thereby rejuvenating cells.
  • the OCT4, SOX1, SOX2, SOX3, GMNN is a human protein, or a non-human protein, e.g., a mammal (e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird), or a protein that has at least 80% identity with the amino acid sequence of the corresponding human protein or non-human protein and maintains activity.
  • a mammal e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird
  • a protein that has at least 80% identity with the amino acid sequence of the corresponding human protein or non-human protein and maintains activity e.g., a mammal (e.g., mouse, rat, bovine, ovine, equine, canine, feline, porcine , monkey, chicken, duck, goose, bird), or a
  • the OCT4, SOX1, SOX2, SOX3, GMNN is a nucleic acid encoding a human protein, or a nucleic acid encoding a non-human protein, e.g., encoding a mammal (e.g., mouse, rat, cow, sheep, horse, dog, cat, pig, monkey, chicken, duck, goose, bird), or have at least 80% identity and maintain identity with the corresponding nucleic acid encoding a human protein, or a nucleic acid sequence encoding a non-human protein Active nucleic acids.
  • a mammal e.g., mouse, rat, cow, sheep, horse, dog, cat, pig, monkey, chicken, duck, goose, bird
  • the present invention provides use of the composition of the first aspect in the preparation of a medicament for rejuvenating cells, tissues or organs of a subject.
  • said rejuvenating a subject's cells, tissues, or organs includes restoring a transcriptional profile or expression in said at least one cell, tissue, or organ that is lost due to aging, injury, disease, or any combination thereof. Genetic information.
  • rejuvenating a subject's cells, tissues or organs includes restoring the function of the cells, increasing the potential of the cells, enhancing the viability of the cells, or increasing the ability of the cells to replicate, or Lifespan, or a combination thereof.
  • the rejuvenating cells, tissues or organs of the subject includes promoting axonal regeneration of neuronal cells in the subject; proliferating fibroblasts in the skin of the subject; promoting chondrocyte proliferation in the subject; Promote the proliferation of muscle stem cells in subjects; reverse the aging of skin fibroblasts in subjects; reverse the aging of cartilage cells.
  • the subject has, is suspected of having, or is at risk of:
  • the diseases, conditions or symptoms associated with impaired cell, tissue or organ viability or aging are, for example, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, inflammatory diseases, skin-related symptoms or disease, eye disease, or disease related to the reproductive system;
  • the neurodegenerative diseases include stroke, Huntington's disease, Alzheimer's disease, Alzheimer's disease, and Parkinson's disease;
  • cardiovascular diseases are hypertension, coronary heart disease arrhythmia, heart disease, hypotension, heart failure, angina pectoris, arteriosclerosis, myocardial infarction, myocarditis, congestive heart failure, atrioventricular block, atherosclerosis, myocardium infarction;
  • the metabolic diseases are type I diabetes, type II diabetes, hyperglycemia, hyperinsulinemia, insulin resistance, obesity, and gout;
  • the musculoskeletal diseases are muscular dystrophy, myasthenia, myasthenia gravis, osteoporosis, osteoarthritis, osteochondrosis, osteochondritis, osteonecrosis, and osteopenia;
  • the inflammatory diseases are systemic lupus erythematosus, polymyalgia rheumatica, gouty arthritis, degenerative arthritis, rheumatoid arthritis, inflammatory arthritis, Hashimoto's thyroiditis, inflammatory bowel disease, hepatitis, Pneumonia, respiratory tract inflammation, encephalitis;
  • the skin-related signs of aging or diseases include wrinkles, age spots, seborrheic keratosis, tinea pedis, measles, neurodermatitis, and nevus;
  • the eye diseases are macular degeneration, retinal degeneration, retinal detachment, diabetic retinopathy, glaucoma, optic atrophy, floaters, cataracts, non-arteritic anterior ischemic optic neuropathy, chorioretinitis, pigmented retina inflammation, traumatic optic neuropathy, compressive optic neuropathy;
  • the methods induce cellular reprogramming, reverse aging, improve tissue function, improve organ function, promote tissue repair, promote tissue survival, promote tissue regeneration, promote tissue growth, promote angiogenesis, reduce scarring, alleviate External manifestations of aging, including alopecia, thinning hair, graying of hair, sagging skin and skin wrinkles, promoting organ regeneration, promoting organ survival, treating disease, or any combination thereof.
  • the methods reverse senescence of cells, tissues, organs, or subjects, thereby rejuvenating said cells, tissues, organs.
  • the methods can promote axonal regeneration of neuronal cells in a subject.
  • the methods can proliferate skin fibroblasts in a subject.
  • the composition can promote chondrocyte proliferation in a subject.
  • the methods can promote muscle stem cell proliferation in a subject.
  • the methods can reverse senescence in a subject's skin fibroblasts.
  • the composition can reverse chondrocyte senescence.
  • the methods do not induce teratoma formation.
  • the methods do not induce complete reprogramming.
  • the methods do not reprogram the cells to an induced pluripotent stem cell (ipsc) state.
  • ipsc induced pluripotent stem cell
  • OCT4, SOX2, KLF4 and c-Myc are four "Yamanaka factors” capable of reprogramming cells into a pluripotent state.
  • these four "Yamanaka factors” can also reprogram senescent cells into young cells.
  • inducing the expression of the four transcription factors in mice carries safety risks and factors that lead to the formation of teratomas in the body. The more it is, the more likely it is to bring about uncertainty in body regulation.
  • the present invention unexpectedly found that in the absence of KLF4 and c-Myc, OCT4 alone, or OCT4 only in combination with any one of SOX1, SOX2, SOX3 and GMNN, can also achieve the reversal of senescent cells.
  • “Factor” in the present invention refers to a biologically active protein, or nucleic acid encoding it, such as DNA or RNA or a mixture thereof, which acts on cells to change transcription, and which, after expression, will cause aging and incapacity. Cells transform into young and energetic cells.
  • the factors may be non-integrating, ie, provided to the recipient somatic cell in a form that does not result in integration of exogenous DNA into the genome of the recipient cell.
  • Factors in the present invention may be transcription factors, including but not limited to OCT4, SOX1, SOX2, SOX3, and GMNN.
  • Figure 1 shows that the composition of the present invention can promote axon regeneration of neuronal cells.
  • Figure 2 shows that the composition of the present invention can promote the proliferation of skin fibroblasts.
  • Figure 3 shows that the composition of the present invention can promote the proliferation of mouse chondrocytes.
  • Figure 4 shows that the composition of the present invention can promote the proliferation of muscle stem cells in aged mice.
  • Figure 5 shows that the composition of the present invention can reverse the aging of skin fibroblasts in aged mice.
  • Figure 6 shows that the composition of the present invention can reverse the aging of chondrocytes.
  • OCT4 is named A
  • SOX2 is named B
  • SOX1 is named C1
  • SOX3 is named C2
  • GMNN is named C3.
  • the OCT4, SOX1, SOX2, SOX3, and GMNN used in the embodiments are all human OCT4, human SOX1, human SOX2, human SOX3, and human GMNN.
  • Example 1 Composition promotes axon regeneration of neuronal cells
  • the main purpose of this example is to select SH-SY5Y (human neuroblastoma cell line) cells, differentiate them into neuronal cells, and determine the regenerative effects of different compositions on neuronal cells.
  • SH-SY5Y human neuroblastoma cell line
  • EMEM/F12 medium (1:1) containing 2.5% FBS, 1 ⁇ PS and 10 ⁇ M all-trans retinoic acid (ATRA, Stemcell Technologies, 72264) (differentiation medium 1)
  • ATRA all-trans retinoic acid
  • Cells were induced to differentiate for 3 days and then incubated for 3 days in EMEM/F12 (1:1) (differentiation medium 2) containing 1% FBS, 1 ⁇ PS and 10 ⁇ M ATRA.
  • the cells were then seeded on cell culture plates coated with poly-D-lysine (ThermoFisher Scientific, A3890401) and cultured for 1 day.
  • the medium was replaced with serum-free serum containing 1 ⁇ Glutamax (ThermoFisher Scientific, 35050061), PS and BDNF.
  • B27 neuronal medium differentiated medium 3
  • differentiation medium 3 B27 neuronal medium
  • a alone, A and B or the combination of A and C can promote the increase of neurite area.
  • Example 2 Composition promotes proliferation of skin fibroblasts in aged mice
  • the main purpose of this embodiment is to select skin cells of aged mice and observe whether the proliferation ability of skin cells in aged mice is enhanced by administering the drug.
  • the specific methods and results are as follows:
  • mice 20-month old mice were selected. After the mice were euthanized, the shaved back skin was excised. Before the skin was removed, it was washed with iodophor (povidone iodine) and rinsed with cold 1 ⁇ PBS.
  • Mouse skin fibroblasts were isolated using trypsin and collagenase. Fibroblasts were resuspended and cultured in DMEM glutamax medium. The cells are treated with the mRNA drug of the target composition, and the cells are collected after 6 days to detect whether the proliferation ability of the aged skin fibroblasts is enhanced.
  • a alone, A and B or a combination of A and C can significantly increase the proliferation ability of skin cells.
  • Example 3 Composition promotes proliferation of chondrocytes in aged mice
  • the main purpose of this embodiment is to select elderly mice, isolate chondrocytes, and observe whether the chondrocytes have stronger proliferation ability.
  • the specific methods and results are as follows:
  • Methods Select 18-month-old elderly mice, isolate the mouse articular cartilage, gently stir the tissue fragments to separate the soft tissue, transfer the remaining cartilage fragments to a new petri dish, and digest the articular cartilage overnight. Pass the collagenase solution through a pipette in order to disperse cell aggregates to form a suspension of separated cells, wash with PBS, resuspend with culture medium, and centrifuge. The chondrocyte proliferation ability was detected 6 days after administration.
  • a alone, A and B or a combination of A and C can significantly promote the proliferation of chondrocytes.
  • Example 4 Composition promotes proliferation of muscle stem cells in aged mice
  • the main purpose of this example is to select aged mice, isolate muscle stem cells (MuSC), and observe whether the muscle stem cells have stronger proliferation ability after drug treatment.
  • the specific methods and results are as follows:
  • mice 15-month old mice were selected, sacrificed by cervical dislocation, the muscles were isolated, cut into small pieces, and cultured in DMEM medium (DMEM; ThermoFisher Scientific) containing 0.2% type I collagenase (Sigma-Aldrich). Incubate at 37°C for 2 hours. Single fibers were collected using a pipette tip and cultured in DMEM containing 1 g/l glucose (supplemented with 10% horse serum (HS, ThermoFisher Scientific), 1% penicillin/streptomycin (ThermoFisher Scientific) and 0.5% chicken embryo extract ( CEE, ThermoFisher Scientific)) was purified twice.
  • DMEM DMEM
  • ThermoFisher Scientific ThermoFisher Scientific
  • CEE chicken embryo extract
  • the obtained stem cells were plated directly on a culture dish coated with Matrigel Growth Factor (GFR) basement membrane matrix (Corning) or a culture dish containing a coverslip coated with Matrigel GFR basement membrane matrix.
  • GFR Matrigel Growth Factor
  • Cells were expanded in DMEM containing 1 g/l glucose and supplemented with 10% HS, 20% FBS, 1% PS and 0.5% CEE and cultured at 37°C, 5% CO with culture changes every 2 days. base. After being treated with different compositions for 6 days, the proliferation ability of the cells was observed.
  • a alone, A and B or the combination of A and C can significantly promote the proliferation of muscle stem cells.
  • Example 5 Composition reverses aging of skin fibroblasts in aged mice
  • the main purpose of this embodiment is to select skin cells of aged mice and observe whether the activity of the aging marker ⁇ -galactosidase in the skin cells of aged mice is changed through administration.
  • the specific methods and results are as follows:
  • a alone, A and B, or the combination of A and C can significantly reverse the aging of skin fibroblasts in aged mice.
  • Example 6 Composition reverses aging of chondrocytes
  • the main purpose of this example is to select chondrocytes, use 20 ⁇ M etoposide to induce senescence, and then examine the change of the composition on the activity of the aging marker ⁇ -galactosidase in the cells.
  • the specific methods and results are as follows:
  • a alone, A and B or the combination of A and C can significantly reverse the aging of chondrocytes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition pour le rajeunissement de cellules, de tissus ou d'organes d'un sujet sur la base de deux facteurs, et un procédé de rajeunissement de cellules, de tissus ou d'organes d'un sujet à l'aide de ladite composition. La composition et le procédé sont capables de provoquer le rajeunissement ou la récupération de la fonction de cellules, de tissus ou d'organes chez un sujet.
PCT/CN2023/107076 2022-07-12 2023-07-12 Composition et son procédé d'utilisation WO2024012502A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210815986.2 2022-07-12
CN202210815986 2022-07-12

Publications (1)

Publication Number Publication Date
WO2024012502A1 true WO2024012502A1 (fr) 2024-01-18

Family

ID=89535633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/107076 WO2024012502A1 (fr) 2022-07-12 2023-07-12 Composition et son procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2024012502A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016043410A1 (fr) * 2014-09-18 2016-03-24 서울대학교산학협력단 Cellules souches mésenchymateuses surexprimant oct4 et sox2, et leur utilisation
CN107810268A (zh) * 2015-05-19 2018-03-16 思特科技公司 通过直接重编程由引入Oct4的人体细胞诱导少突胶质细胞前体细胞的方法
US20180346933A1 (en) * 2015-11-23 2018-12-06 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for reprogramming cells
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
CN113453702A (zh) * 2018-09-28 2021-09-28 哈佛大学的校长及成员们 细胞重编程以逆转衰老并促进组织和组织再生
CN115247152A (zh) * 2022-09-21 2022-10-28 呈诺再生医学科技(北京)有限公司 制备造血干细胞或造血干祖细胞的方法及培养长期再生造血干细胞的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016043410A1 (fr) * 2014-09-18 2016-03-24 서울대학교산학협력단 Cellules souches mésenchymateuses surexprimant oct4 et sox2, et leur utilisation
CN107810268A (zh) * 2015-05-19 2018-03-16 思特科技公司 通过直接重编程由引入Oct4的人体细胞诱导少突胶质细胞前体细胞的方法
US20180346933A1 (en) * 2015-11-23 2018-12-06 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for reprogramming cells
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
CN113453702A (zh) * 2018-09-28 2021-09-28 哈佛大学的校长及成员们 细胞重编程以逆转衰老并促进组织和组织再生
CN115247152A (zh) * 2022-09-21 2022-10-28 呈诺再生医学科技(北京)有限公司 制备造血干细胞或造血干祖细胞的方法及培养长期再生造血干细胞的方法

Similar Documents

Publication Publication Date Title
Taghipour et al. Transplantation of undifferentiated and induced human exfoliated deciduous teeth-derived stem cells promote functional recovery of rat spinal cord contusion injury model
Guo et al. Cotransplant of neural stem cells and NT-3 gene modified Schwann cells promote the recovery of transected spinal cord injury
Wijeyekoon et al. Cell replacement therapy for Parkinson's disease
US20060247195A1 (en) Method of altering cell properties by administering rna
US20020098584A1 (en) Postmortem stem cells
KR20060037346A (ko) 휘돌기교세포 전구세포 및 이를 획득하고 배양하는 방법
US20160011177A1 (en) Screening method for therapeutic agents for charcot-marie-tooth disease and self-differentiation motor neurons used therefor
JP2004511266A (ja) 間葉間質細胞に対する治療的利用法
Cantini et al. Gene transfer into satellite cell from regenerating muscle: bupivacaine allows β-gal transfection and expression in vitro and in vivo
Upadhyay Role of regeneration in tissue repairing and therapies
Mellott et al. Nonviral reprogramming of human wharton's jelly cells reveals differences between ATOH1 homologues
WO2024012502A1 (fr) Composition et son procédé d'utilisation
WO2024012504A1 (fr) Composition et son procédé d'utilisation
WO2024012503A1 (fr) Composition et sa méthode d'utilisation
WO2019014553A1 (fr) Induction de cellules progénitrices neurales, de cellules progénitrices d'oligodendrocytes et d'oligodendrocytes par différenciation de cellules souches à l'aide de facteurs de transcription de points de repère
CN111484977B (zh) 重编程产生功能性去甲肾上腺素能神经元的方法
US11261461B2 (en) Methods and compositions for selective generation of dopaminergic precursors
BR112021003791A2 (pt) composição e método para a reprogramação direta de células urinárias em células-tronco neurais, e, composição farmacêutica.
US10421944B2 (en) Method for producing neural stem cells using synthetic peptide
CA2595528A1 (fr) Methode de traitement par administration d'arn
WO2024071382A1 (fr) Cellule souche pluripotente et cellule différenciée et induite à partir d'une cellule souche ayant une fonction de sécrétion de glp-1
JP7300764B2 (ja) 細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途
US20060263876A1 (en) Neural crest stem cells and uses thereof
US20090208465A1 (en) Method of treating neural defects
WO2002034889A2 (fr) Utilisations therapeutiques de cellules stromales mesenchymateuses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23838992

Country of ref document: EP

Kind code of ref document: A1